Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 6Sarcoma 2Gastrointestinal 1

Conditions

Neurofibrosarcoma 2Neurofibromatosis 1 2Sarcoma 1

Interventions

Doxorubicin 5Cyclophosphamide 4anlotinib 3Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Neoadjuvant Therapy 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1spartalizumab 1relmacabtagene autoleucel 1regorafenib 1penpulimab 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × AZD 6244 × Sarcoma × Clear all
NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

University of Alabama at Birmingham

Phase 2 Not yet recruiting
41 enrolled
CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT06735820 2025-07-03

MEKMDM2

Children's National Research Institute

Phase 1/2 Not yet recruiting
45 enrolled
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡